Assistant Professor, Medicine (Oncology)
Albert Einstein College of Medicine
Bronx, New York
Triple negative breast cancer (TNBC) comprises approximately 15%-20% of all breast cancers. These aggressive tumors are treated with a cocktail of chemotherapy drugs; however almost two-thirds of patients do not respond and additionally suffer significant side effects, some of which are long-lasting and prevent them from receiving future therapy. The BCRF research of Drs. McDaid and Horwitz is focused on developmental therapeutics with maximal anti-tumor efficacy and minimal toxicity to improve the outcome of TNBC patients. In testing a panel of drugs in TNBC tumor cells they identified a promising new compound that is as effective as, but less toxic then Taxol, a powerful chemotherapy drug used to treat TNBC. They will continue testing additional structural analogues of this lead compound to obtain a drug with maximum tumor cell kill ability coupled with a low toxicity profile.
Dr. Hayley McDaid received her PhD from the Queens University of Belfast, where she characterized the role of the cAMP-dependent protein kinase A signaling pathway in breast and ovarian cancer. These studies pioneered her present-day interest in targeted therapies, pharmacogenomics and rationally designed drug combinations.
Dr. McDaid's broad research theme in breast cancer is focused on investigating molecular mechanisms of action and resistance to novel therapeutics. She is interested in defining the ‘circuitry’ of breast cancer in the different molecular subtypes of triple negative tumors; and mechanisms by which tumors counteract the effects of therapy. As part of this focus, Dr. McDaid has been studying chemotherapy-mediated senescence, a type of growth arrest that is increasingly perceived as a deleterious outcome of treatment. Together with colleagues, she is interested in chemical-biological approaches to minimize the risk of developing senescence during treatment.